Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lessons for patients with MS and COVID-19

Publish date:: September 12, 2020

Key clinical point: Patients with MS and COVID-19 could avoid infection reactivation and continue MS therapies during virus treatment.

Major finding: Only 17% of MS patients with COVID-19 required hospitalization.

Study details: Observational, prospective and clinical practice studies of a multidisciplinary protocol of 90 patients with MS and COVID-19 and real-world evaluation of 41 COVID-19-infected patients with MS.

Disclosures: Virginia Meca-Lallana, MD, has no relevant financial disclosures.

Citation:

Meca-Lallana V, et al. MSVirtual2020. Abstracts P0025 and P0079.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,